Federated Investors Boosted Heron Therapeutics (HRTX) Position; Stone Ridge Asset Management Decreased Its Merck & Co (MRK) Stake

August 12, 2018 - By Lisa Delgado

Merck & Co., Inc. (NYSE:MRK) Logo

Stone Ridge Asset Management Llc decreased Merck & Co Inc (MRK) stake by 74.56% reported in 2018Q1 SEC filing. Stone Ridge Asset Management Llc sold 30,400 shares as Merck & Co Inc (MRK)’s stock rose 5.40%. The Stone Ridge Asset Management Llc holds 10,375 shares with $565,000 value, down from 40,775 last quarter. Merck & Co Inc now has $175.72 billion valuation. The stock increased 0.11% or $0.07 during the last trading session, reaching $66.07. About 7.44 million shares traded. Merck & Co., Inc. (NYSE:MRK) has declined 9.15% since August 12, 2017 and is downtrending. It has underperformed by 21.72% the S&P500. Some Historical MRK News: 07/03/2018 – MERCK – TO PAY EISAI UPFRONT PAYMENT OF $300 MLN U.S. DOLLARS AND UP TO $650 MILLION U.S. DOLLARS FOR CERTAIN OPTION RIGHTS THROUGH 2020 AS PER DEAL; 31/05/2018 – Merck and Premier Inc. Collaborating to Help Reduce Clostridium difficile (C. diff) Infection; 18/04/2018 – Merck KGaA Has Been Exploring Options for Consumer Health Unit; 07/05/2018 – Genmab Announces U.S. FDA Approval of DARZALEX® (daratumumab) in Newly Diagnosed Multiple Myeloma; 23/05/2018 – MERCK & CO – SUBMITTED SBLA FOR KEYTRUDA IN COMBINATION TO U.S. FDA AND NEW DATA WILL BE SHARED WITH AGENCY; 09/04/2018 – KEYTRUDA® (pembrolizumab) Monotherapy Met Primary Endpoint in Phase 3 KEYNOTE-042 Study, Significantly Improving OS as First-Line Therapy in Locally Advanced or Metastatic NSCLC Patients Expressing PD-L1 in at Least 1 Percent of Tumor; 06/04/2018 – NewLink Genetics: Review Follows Earlier Incyte, Merck Announcement; 21/05/2018 – Congo begins giving experimental Ebola vaccine to medics; 30/04/2018 – MRK: SBLA FOR KEYTRUDA COMBO WITH ALIMTA AND PLATINUM CHEMO; 08/03/2018 – MERCK KGAA CEO SAYS STILL SEE MAVENCLAD PEAK SALES OF 500-700 MLN EUR EXCLUDING U.S

Federated Investors Inc increased Heron Therapeutics Inc (HRTX) stake by 28.92% reported in 2018Q1 SEC filing. Federated Investors Inc acquired 20,708 shares as Heron Therapeutics Inc (HRTX)’s stock rose 38.85%. The Federated Investors Inc holds 92,305 shares with $2.55 million value, up from 71,597 last quarter. Heron Therapeutics Inc now has $2.98B valuation. The stock decreased 0.77% or $0.3 during the last trading session, reaching $38.7. About 657,745 shares traded. Heron Therapeutics, Inc. (NASDAQ:HRTX) has risen 111.78% since August 12, 2017 and is uptrending. It has outperformed by 99.21% the S&P500. Some Historical HRTX News: 18/05/2018 – Patrick Heron at Tate St Ives – a Cornish cornucopia; 02/04/2018 – Heron Preston on Breaking the Rules; 28/03/2018 – Heron Therapeutics Announces Proposed Public Offering of Common Stk; 19/03/2018 – HERON THERAPEUTICS INC – SIGNIFICANTLY FEWER HTX-011 PATIENTS EXPERIENCED SEVERE PAIN AT ANY TIME; 09/05/2018 – Eagle Asset Buys New 2.5% Position in Heron Therapeutics; 10/05/2018 – Heron Therapeutics 1Q Loss $52.3M; 09/05/2018 – DURECT Announces Amendment to Licensing Agreement with Sandoz Related to POSIMIR® (SABER®-Bupivacaine); 19/04/2018 – Heron’s Drilling Delivers Massive Sulphide lntercepts at G2 and Lisa Lenses; 18/05/2018 – Cornish cornucopia: Patrick Heron at Tate St Ives; 04/04/2018 – Work Capital Announces New Partnership with the Heron Foundation

Among 8 analysts covering Heron Therapeutics (NASDAQ:HRTX), 8 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Heron Therapeutics had 17 analyst reports since February 16, 2018 according to SRatingsIntel. The firm has “Buy” rating given on Tuesday, February 27 by Cantor Fitzgerald. The stock of Heron Therapeutics, Inc. (NASDAQ:HRTX) has “Buy” rating given on Monday, March 19 by Needham. The stock has “Outperform” rating by Evercore on Thursday, June 21. The stock has “Buy” rating by Evercore on Thursday, April 5. The firm has “Buy” rating by Northland Capital given on Monday, March 26. The stock of Heron Therapeutics, Inc. (NASDAQ:HRTX) earned “Buy” rating by Oppenheimer on Tuesday, March 27. Cantor Fitzgerald maintained the stock with “Buy” rating in Monday, March 19 report. On Sunday, April 22 the stock rating was maintained by Cantor Fitzgerald with “Buy”. Oppenheimer maintained Heron Therapeutics, Inc. (NASDAQ:HRTX) rating on Monday, March 19. Oppenheimer has “Buy” rating and $34.0 target. Cantor Fitzgerald maintained Heron Therapeutics, Inc. (NASDAQ:HRTX) on Thursday, July 19 with “Overweight” rating.

More recent Heron Therapeutics, Inc. (NASDAQ:HRTX) news were published by: Fool.com which released: “2 Growth Stocks That Could Make You Rich” on August 09, 2018. Also Fool.com published the news titled: “Why Pacira Pharmaceuticals Stock Is on the Rise Today” on July 26, 2018. Streetinsider.com‘s news article titled: “Heron Therapeutics (HRTX) PT Raised to $50 at Cantor Fitzgerald” with publication date: July 19, 2018 was also an interesting one.

Federated Investors Inc decreased Bank Amer Corp (NYSE:BAC) stake by 98,958 shares to 5.02M valued at $150.47 million in 2018Q1. It also reduced Lakeland Finl Corp (NASDAQ:LKFN) stake by 14,693 shares and now owns 295 shares. Insmed Inc (NASDAQ:INSM) was reduced too.

More important recent Merck & Co., Inc. (NYSE:MRK) news were published by: Finance.Yahoo.com which released: “You Better Be Careful with Merck Stock, Especially at These Highs” on August 10, 2018, also Benzinga.com published article titled: “Merck Announces Plans To Cut Drug Prices”, 247Wallst.com published: “Merck Underwhelms Despite Beating Earnings” on July 27, 2018. More interesting news about Merck & Co., Inc. (NYSE:MRK) was released by: 247Wallst.com and their article: “Short Sellers Hike Bets in Major Pharma Stocks” with publication date: August 10, 2018.

Analysts await Merck & Co., Inc. (NYSE:MRK) to report earnings on October, 26. They expect $1.14 EPS, up 2.70% or $0.03 from last year’s $1.11 per share. MRK’s profit will be $3.03 billion for 14.49 P/E if the $1.14 EPS becomes a reality. After $1.06 actual EPS reported by Merck & Co., Inc. for the previous quarter, Wall Street now forecasts 7.55% EPS growth.

Among 11 analysts covering Merck \u0026 Co (NYSE:MRK), 9 have Buy rating, 0 Sell and 2 Hold. Therefore 82% are positive. Merck \u0026 Co had 15 analyst reports since February 13, 2018 according to SRatingsIntel. The stock has “Overweight” rating by Barclays Capital on Thursday, April 5. The firm earned “Hold” rating on Friday, April 20 by Cowen & Co. BMO Capital Markets maintained Merck & Co., Inc. (NYSE:MRK) rating on Wednesday, February 14. BMO Capital Markets has “Outperform” rating and $65 target. The company was maintained on Friday, April 13 by Jefferies. The stock has “Buy” rating by Bank of America on Tuesday, April 17. The rating was upgraded by Leerink Swann to “Buy” on Monday, March 12. The rating was maintained by Credit Suisse on Wednesday, February 14 with “Outperform”. Guggenheim maintained the stock with “Buy” rating in Tuesday, April 17 report. Jefferies maintained the stock with “Hold” rating in Monday, February 26 report. The stock of Merck & Co., Inc. (NYSE:MRK) has “Buy” rating given on Monday, July 30 by Bank of America.

Investors sentiment increased to 1 in Q1 2018. Its up 0.06, from 0.94 in 2017Q4. It is positive, as 72 investors sold MRK shares while 603 reduced holdings. 114 funds opened positions while 561 raised stakes. 1.91 billion shares or 1.08% less from 1.93 billion shares in 2017Q4 were reported. First Amer Bank stated it has 0.55% of its portfolio in Merck & Co., Inc. (NYSE:MRK). 91,851 are owned by Jefferies Group Ltd Liability Corp. Bourgeon Cap Mngmt Ltd Llc reported 127,090 shares. First Citizens National Bank Tru accumulated 0.15% or 19,714 shares. Stellar Capital Lc has invested 2.37% of its portfolio in Merck & Co., Inc. (NYSE:MRK). Of Virginia Lc invested 0.71% of its portfolio in Merck & Co., Inc. (NYSE:MRK). Washington holds 46,506 shares. Strategic Advsr Limited Liability has 0.55% invested in Merck & Co., Inc. (NYSE:MRK). Brighton Jones Limited Liability Corporation accumulated 0.18% or 23,334 shares. Nomura Asset Mgmt Ltd reported 1.24M shares. Jpmorgan Chase And reported 38.06M shares. Renaissance Investment Grp Incorporated Ltd holds 1.74% of its portfolio in Merck & Co., Inc. (NYSE:MRK) for 78,892 shares. Sumitomo Mitsui Trust stated it has 8.26 million shares. Plancorp Ltd Liability Co has invested 0.36% of its portfolio in Merck & Co., Inc. (NYSE:MRK). Pinnacle Associate Limited stated it has 0.57% in Merck & Co., Inc. (NYSE:MRK).

Stone Ridge Asset Management Llc increased Clorox Co Del (NYSE:CLX) stake by 2,700 shares to 13,232 valued at $1.76M in 2018Q1. It also upped Johnson & Johnson (NYSE:JNJ) stake by 85,800 shares and now owns 102,877 shares. Littelfuse Inc (NASDAQ:LFUS) was raised too.

Merck & Co., Inc. (NYSE:MRK) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts